|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
On the contrary, the randomized TNT trial showed a significant benefit for carboplatin vs docetaxel in terms of response rate and PFS specifically in patients with advanced gBRCA -associated tumors.
|
30819448 |
2019 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Moreover, after in vivo administration, the betaG enzyme was shown to localize to tumor and remain active for up to 9 days demonstrating a key characteristic of TNT targeting.
|
12954121 |
2003 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Together, these results suggest that TNF-enhanced tk gene therapy should provide a useful treatment for TNF-alpha-sensitive tumors and perhaps also for TNT-alpha-resistant tumors if vector delivery can be improved to increase the percentage of transduced tumor cells.
|
9865731 |
1998 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
TNT, or systemic chemotherapy followed by chemoradiation (CRT), addresses both occult metastases and positive margin risks and thus is a potentially optimal strategy; however, factors predictive of perioperative and survival outcomes are currently undefined.
|
30946090 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
|
29713086 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
|
29713086 |
2018 |
|
Neoplasm Metastasis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study).
|
26253814 |
2015 |
|
Triple Negative Breast Neoplasms
|
0.020 |
Biomarker
|
disease |
BEFREE |
Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study).
|
26253814 |
2015 |
|
Triple-Negative Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study).
|
26253814 |
2015 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
TNT, or systemic chemotherapy followed by chemoradiation (CRT), addresses both occult metastases and positive margin risks and thus is a potentially optimal strategy; however, factors predictive of perioperative and survival outcomes are currently undefined.
|
30946090 |
2019 |
|
Fabry Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001].
|
30233871 |
2018 |
|
Coronary Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C.
|
29618599 |
2018 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C.
|
29618599 |
2018 |
|
Friedreich Ataxia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001].
|
30233871 |
2018 |
|
Kidney Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two reviewers independently extracted data using a standardized data extraction protocol where TNI or TNT concentrations; total TNI released after cardiac surgery; and the incidence of AKI, AMI, and mortality were recorded.
|
29210794 |
2018 |
|
Senile cardiac amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001].
|
30233871 |
2018 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C.
|
29618599 |
2018 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
High-dose atorvastatin significantly reduced cardiovascular events vs. standard/low-dose statins in patients without psoriasis in TNT/IDEAL; similar numeric differences in event rates were observed in patients with psoriasis.
|
28573499 |
2017 |
|
Metastatic human epidermal growth factor 2 positive carcinoma of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigates the outcome (overall survival [OS] and time to next treatment [TNT]) in MBC patients pretreated with trastuzumab in the adjuvant setting (TP-group) compared with trastuzumab-naïve patients (TN-group) in order to investigate the possibility of trastuzumab resistance.
|
28533475 |
2017 |
|
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover: (1) 26 patients achieving major MRD response (67%) benefit of excellent disease control (median TNT: 42 months); (2) MRD reappearance heralds relapse, with a TNT comparable to that of MRD persistence (9 versus 10 months, P=0.706); (3) the median lag between MRD reappearance and need for salvage treatment is 9 months.
|
25027515 |
2015 |
|
Myopathies, Nemaline
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A lethal form of nemaline myopathy, named "Amish Nemaline Myopathy" (ANM), is linked to a nonsense mutation at codon Glu180 in the slow skeletal muscle troponin T (TnT) gene.
|
12732643 |
2003 |
|
NEMALINE MYOPATHY 5
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A lethal form of nemaline myopathy, named "Amish Nemaline Myopathy" (ANM), is linked to a nonsense mutation at codon Glu180 in the slow skeletal muscle troponin T (TnT) gene.
|
12732643 |
2003 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Because TNT-3 recognizes a universal nuclear antigen accessible in degenerating and necrotic cells within all solid tumors, this strategy may be applicable to the majority of human cancers.
|
9918202 |
1999 |